OBJECTIVES: The aim of the study was to describe agreement between the QRISK2, Framingham and Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) cardiovascular disease (CVD) risk calculators in a large UK study of people living with HIV (PLWH). METHODS: PLWH enrolled in the Pharmacokinetic and Clinical Observations in People over Fifty (POPPY) study without a prior CVD event were included in this study. QRISK2, Framingham CVD and the full and reduced D:A:D CVD scores were calculated; participants were stratified into 'low' ( 20%) categories for each. Agreement between scores was assessed using weighted kappas and Bland-Altman plots. RESULTS: The 730 included participants were predominantly male (636; 87.1%) and of white ethnicity (...
Background With the aging of the population living with HIV, the absolute risk of cardiovascular dis...
This study aims to estimate the risk of cardiovascular disease (CVD) and to assess the agreement bet...
Importance: Commonly used risk assessment tools for cardiovascular disease might not be accurate for...
Objectives The aim of the study was to describe agreement between the QRISK2, Framingham and Data C...
Background Cardiovascular disease (CVD) is a major cause of mortality in HIV infected patients. Agr...
AIMS We prospectively assessed and compared the accuracy of cardiovascular risk scores in people ...
We prospectively assessed and compared the accuracy of cardiovascular risk scores in people living w...
Objectives: The aim of the study was to compare the predictions of five popular cardiovascular disea...
People living with HIV (PLHIV) have twice the risk of developing cardiovascular diseases, making it ...
Abstract Background The Absolute cardiovascular disease (CVD) risk evaluation using multivariable CV...
BACKGROUND: People living with HIV (PLWH) experience a higher cardiovascular disease (CVD) risk. Yet...
Introduction: Cardiovascular disease (CVD) is the leading cause of death in England and Wales. As pe...
AIMS: HIV-infected patients receiving combination antiretroviral therapy may experience metabolic c...
HIV-infected patients receiving combination antiretroviral therapy may experience metabolic complica...
The relationship between HIV and cardiovascular diseases (CVDs) remains complex. The aim of this stu...
Background With the aging of the population living with HIV, the absolute risk of cardiovascular dis...
This study aims to estimate the risk of cardiovascular disease (CVD) and to assess the agreement bet...
Importance: Commonly used risk assessment tools for cardiovascular disease might not be accurate for...
Objectives The aim of the study was to describe agreement between the QRISK2, Framingham and Data C...
Background Cardiovascular disease (CVD) is a major cause of mortality in HIV infected patients. Agr...
AIMS We prospectively assessed and compared the accuracy of cardiovascular risk scores in people ...
We prospectively assessed and compared the accuracy of cardiovascular risk scores in people living w...
Objectives: The aim of the study was to compare the predictions of five popular cardiovascular disea...
People living with HIV (PLHIV) have twice the risk of developing cardiovascular diseases, making it ...
Abstract Background The Absolute cardiovascular disease (CVD) risk evaluation using multivariable CV...
BACKGROUND: People living with HIV (PLWH) experience a higher cardiovascular disease (CVD) risk. Yet...
Introduction: Cardiovascular disease (CVD) is the leading cause of death in England and Wales. As pe...
AIMS: HIV-infected patients receiving combination antiretroviral therapy may experience metabolic c...
HIV-infected patients receiving combination antiretroviral therapy may experience metabolic complica...
The relationship between HIV and cardiovascular diseases (CVDs) remains complex. The aim of this stu...
Background With the aging of the population living with HIV, the absolute risk of cardiovascular dis...
This study aims to estimate the risk of cardiovascular disease (CVD) and to assess the agreement bet...
Importance: Commonly used risk assessment tools for cardiovascular disease might not be accurate for...